Publications
484 publications
- Date
- Relevance
-
Belimumab (Benlysta) for the indication ‘active, auto-antibodypositive systemic lupus erythematosus with a high degree of disease activity’
The therapeutic value of adding belimumab to the standard treatment in the treatment of adult patients with active, ...
-
Assessment of the established medical science and practice of immunotherapy ch14.18 + GM-CSF + IL2 for highrisk neuroblastoma
This leads to the outcome of assessment that immunotherapy ch14.18 + GM-CSF + IL2 in cases of high-risk neuroblastoma is still ...
-
Conditional reimbursement of health care
Health care in the insured package must comply with the ‘established medical science and medical practice’ criterion. This ...
-
Rilpivirine-emtricitabine-tenofovir disoproxil (Eviplera) for the indication ‘infection with HIV-1’
For the treatment of adult, therapy-naive patients infected with HIV-1 and with a virus concentration ≤ 100,000 copies/ml, the ...
-
Rilpivirine (Edurant) for the indication ‘infection with HIV-1’
For the treatment of adult, therapy-naive patients infected with HIV-1 and with a virus concentration ≤ 100,000 copies/mL, the ...
-
rituximab (Mabthera) for the indication 'maintenance therapy for patients with follicular lymphoma
For the maintenance treatment of follicular lymphoma patients who respond to first-line induction therapy, rituximab has an added ...
-
Ipilimumab (Yervoy) for ‘treatment of advanced (unresectable or metastatic) melanoma in adults
In a single phase-3 study in patients with advanced (stage III or IV) melanoma who had been treated previously, and had a ...
-
Ranibizumab (Lucentis) for the treatment of neovascular (wet) age-related macular degeneration
The conclusion on t=0 was that ranibizumab could be used for the treatment of minimally classic, predominantly classic and occult ...
-
Fingolimod (Gilenya) for 'relapsing-remitting multiple sclerosis’
In a direct comparison of fingolimod with interferon beta (Avonex) in ambulatory patients with relapsing-remitting multiple ...
-
Denosumab (XGEVA) for the 'prevention of skeletal-related events in adults with bone metastases from solid tumours’
In the treatment of bone metastases from solid tumors, the therapeutic value of s.c. denosumab is comparable with that of i.v. ...